A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)
Trial details
- Registry ID
- NCT06041269
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as ANB030
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)NCT06041269 | ANAB | Phase 2 | Active not recruiting | 2024-11-29Estimated |
| A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)NCT06127043 | ANAB | Phase 2 | Active not recruiting | 2026-01Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |